147 related articles for article (PubMed ID: 20433995)
1. Tissue-factor fusion proteins induce occlusion of tumor vessels.
Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
[TBL] [Abstract][Full Text] [Related]
2. Generation of fusion proteins for selective occlusion of tumor vessels.
Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
[TBL] [Abstract][Full Text] [Related]
3. [Arginine-glycine-aspartic polypeptide mediated truncated tissue factor therapy for colorectal carcinoma].
Huang ZJ; Luo Q; Yan JH; Wang SY
Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(8):619-24. PubMed ID: 20646482
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C
Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410
[TBL] [Abstract][Full Text] [Related]
5. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
[TBL] [Abstract][Full Text] [Related]
6. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
[TBL] [Abstract][Full Text] [Related]
8. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
[TBL] [Abstract][Full Text] [Related]
9. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
[TBL] [Abstract][Full Text] [Related]
10. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis.
Hu P; Yan J; Sharifi J; Bai T; Khawli LA; Epstein AL
Cancer Res; 2003 Aug; 63(16):5046-53. PubMed ID: 12941833
[TBL] [Abstract][Full Text] [Related]
12. [Gene expression and activities analysis of a new fusion protein (RGD) 3/tTF].
Yan JH; Yang GW; Wang JP; Wu N; Zhuang GH
Sheng Wu Gong Cheng Xue Bao; 2007 May; 23(3):409-12. PubMed ID: 17577984
[TBL] [Abstract][Full Text] [Related]
13. [Humanized monoclonal antibody TNT-3-mediated truncated tissue factor for the treatment of H22 hepatoma-bearing mice].
Huang ZJ; Wang R; Liu ZZ; Wang SY; Yan JH; Luo Q
Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):249-53. PubMed ID: 22781034
[TBL] [Abstract][Full Text] [Related]
14. [Expression and characterization of fusion protein tTF/SA as a universal effector for targeting blood coagulation].
Wang Z; Yan JH; Wang JP; Xie LY; Wu N
Sheng Wu Gong Cheng Xue Bao; 2007 Mar; 23(2):218-22. PubMed ID: 17460891
[TBL] [Abstract][Full Text] [Related]
15. High-yield expression, purification and characterization of tumor-targeted IFN-alpha2a.
Meng J; Yan Z; Wu J; Li L; Xue X; Li M; Li W; Hao Q; Wan Y; Qin X; Zhang C; You Y; Han W; Zhang Y
Cytotherapy; 2007; 9(1):60-8. PubMed ID: 17354103
[TBL] [Abstract][Full Text] [Related]
16. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
17. Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor.
Schwöppe C; Zerbst C; Fröhlich M; Schliemann C; Kessler T; Liersch R; Overkamp L; Holtmeier R; Stypmann J; Dreiling A; König S; Höltke C; Lücke M; Müller-Tidow C; Mesters RM; Berdel WE
J Med Chem; 2013 Mar; 56(6):2337-47. PubMed ID: 23496322
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
19. A recombined fusion protein SP5.2/tTF induce thrombosis in tumor blood vessel.
Lv S; Ye M; Wang X; Li Z; Chen X; Dou X; Dai Y; Zeng F; Luo L; Wang C; Li K; Luo X; Yan J; Li X
Neoplasma; 2015; 62(4):531-40. PubMed ID: 25997964
[TBL] [Abstract][Full Text] [Related]
20. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
